David Miller

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial

Daniel F. Hanley, Richard E. Thompson, Michael Rosenblum et al. · The Lancet · 2019 · 850 citations · Full text

Thrombosis, Endpoint Phase 3, Interventional Neuroradiology +12

The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma

Veit J. Erpenbeck, Todor A. Popov, David Miller et al. · Pulmonary Pharmacology & Therapeutics · 2016 · 108 citations

Asthma, Allergy, Uncontrolled Allergic Asthma +8

Effect of sharp debridement using curette on recalcitrant nonhealing venous leg ulcers: A concurrently controlled, prospective cohort study

Dean Williams, Stuart Enoch, David Miller et al. · Wound Repair and Regeneration · 2005 · 104 citations · Full text

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

Antonio Uccelli, Alice Laroni, Rehiana Ali et al. · The Lancet Neurology · 2021 · 99 citations

Regenerative Medicine, Mesenchymal Stem Cells, Cell Therapy +11

Emergency Medical Services Outcomes Project (EMSOP) II: Developing the foundation and conceptual models for out-of-hospital outcomes research

Daniel W. Spaite, Ronald F. Maio, Herbert G. Garrison et al. · Annals of Emergency Medicine · 2001 · 85 citations · Full text

Emergency Response, Emergency Medical Services, Patient Safety +10